California voters will decide Proposition 38 on November 3, 2026, which authorizes $8.4 billion in general obligation bonds to fund immunology and immunotherapy research, with half directed to a University of California-affiliated institute and the balance through competitive grants, at least half of which targets cancer, heart disease, and Alzheimer’s. The measure qualified for the ballot in June 2026 after signature gathering led by philanthropist Gary Michelson and backed by multiple disease advocacy organizations. Trader consensus near 55% for passage reflects the initiative’s organized support and context of federal research funding uncertainty, balanced against fiscal analyses projecting $500–600 million in annual General Fund debt service for roughly two decades, plus concerns over fund allocation concentration and bond suitability for research. No major new developments have shifted positioning since qualification.